120 related articles for article (PubMed ID: 15311888)
21. [Effect and role of anthracyclines in the treatment of metastatic breast cancers].
Herait P
Pathol Biol (Paris); 1990 Oct; 38(8):859. PubMed ID: 2274390
[No Abstract] [Full Text] [Related]
22. Cox-2 expression on tissue microarray of breast cancer.
Park K; Han S; Shin E; Kim HJ; Kim JY
Eur J Surg Oncol; 2006 Dec; 32(10):1093-6. PubMed ID: 16797158
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide, prednisone, staphage lysate and warfarin in disseminated breast cancer.
D'Souza DP; Daly L; Thornes RD
Ir Med J; 1980 Oct; 73(10):385-7. PubMed ID: 7429789
[No Abstract] [Full Text] [Related]
25. Chemotherapy during pregnancy: what is really safe?
Peccatori F; Martinelli G; Gentilini O; Goldhirsch A
Lancet Oncol; 2004 Jul; 5(7):398. PubMed ID: 15231245
[No Abstract] [Full Text] [Related]
26. Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Mehta RS; Schubbert T
J Natl Cancer Inst; 2008 May; 100(9):680; author reply 680-1. PubMed ID: 18445822
[No Abstract] [Full Text] [Related]
27. An intertrigo-like eruption from pegylated liposomal doxorubicin.
Korver GE; Ronald H; Petersen MJ
J Drugs Dermatol; 2006 Oct; 5(9):901-2. PubMed ID: 17039658
[TBL] [Abstract][Full Text] [Related]
28. Caelyx and ovarian cancer.
Eur J Cancer Care (Engl); 2001 Jun; 10(2):79. PubMed ID: 11829050
[No Abstract] [Full Text] [Related]
29. Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.
Byrnes KW; DeBenedetti A; Holm NT; Luke J; Nunez J; Chu QD; Meschonat C; Abreo F; Johnson LW; Li BD
J Am Coll Surg; 2007 May; 204(5):925-33; discussion 933-4. PubMed ID: 17481512
[TBL] [Abstract][Full Text] [Related]
30. [4'-epidoxorubicin].
Mechl Z
Cas Lek Cesk; 1985 Jun; 124(24):755-7. PubMed ID: 3860300
[No Abstract] [Full Text] [Related]
31. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
32. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L; Goh BC; Wong CI; Sukri N; Lim SE; Tan SH; Guo JY; Lim R; Yap HL; Khoo YM; Iau P; Lee HS; Lee SC
Pharmacogenet Genomics; 2008 Jul; 18(7):621-31. PubMed ID: 18551042
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin-induced cardiomyopathy.
Swain SM
N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049087
[No Abstract] [Full Text] [Related]
34. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
35. [1st results of the clinical examination of Adriamycin].
Obrecht P; Westerhausen M; Simon A
Dtsch Med Wochenschr; 1971 Feb; 96(9):369-76. PubMed ID: 4925338
[No Abstract] [Full Text] [Related]
36. Doxorubicin-induced second degree and complete atrioventricular block.
Kilickap S; Akgul E; Aksoy S; Aytemir K; Barista I
Europace; 2005 May; 7(3):227-30. PubMed ID: 15878560
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
38. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?
Bielack SS; Erttmann R; Kempf-Bielack B; Winkler K
Eur J Cancer; 1996 Sep; 32A(10):1652-60. PubMed ID: 8983270
[No Abstract] [Full Text] [Related]
39. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
40. Anthracycline therapy may be avoidable in early breast cancer, new studies suggest.
Tuma R
J Natl Cancer Inst; 2008 Apr; 100(7):459-61. PubMed ID: 18364497
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
